Stock listing
TASE:CANF Can-Fite BioPharma Ltd. מניה
Home listing (TASE) of Can-Fite BioPharma Ltd.
Follow Can-Fite BioPharma Ltd. into a list and get an email when it puts out news.
Share price · TASE:CANF
257.00 ILA (agorot) -12.40 (-4.6%)
Close on Oct 29, 2026
- Day range
- 257.00 – 266.00 ILA (agorot)Oct 29, 2026
- Volume
- 4,877 sharesOct 29, 2026
- Market cap
- 15.58M ILSAt the close on Oct 29, 2026 · price × 6.06M shares outstanding
- Traded on an average day
- 73,536 ILSMedian day 8,201 shares · last 3 months, Jul 29, 2026 – Oct 29, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:CANF · Home | 257.00 ILA (agorot) | -12.40 (-4.6%) | 4,877 | 263.90 | 266.00 | 257.00 | 269.40 | Close on Oct 29, 2026 |
| NYSE American:CANF | $1.65 USD | -0.13 (-7.3%) | 77,863 | $1.65 | $1.71 | $1.635 | $1.78 | Close on Oct 27, 2026 |
Daily closes
Last 3 months, Jul 29, 2026 – Oct 29, 2026 · TASE:CANF · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 257.00 | -12.40 | -4.6% | 263.90 | 266.00 | 257.00 | 4,877 | |
| 269.40 | +1.40 | +0.5% | 278.90 | 281.40 | 260.60 | 10,900 | |
| 268.00 | -40.50 | -13.1% | 293.00 | 325.00 | 257.30 | 127,772 | |
| 308.50 | +9.50 | +3.2% | 306.00 | 308.50 | 298.60 | 6,383 | |
| 299.00 | -1.20 | -0.4% | 305.00 | 309.40 | 299.00 | 426 | |
| 300.20 | -5.40 | -1.8% | 310.00 | 310.00 | 300.20 | 2,000 | |
| 305.60 | -1.40 | -0.5% | 313.50 | 313.50 | 299.00 | 16,358 | |
| 307.00 | -4.90 | -1.6% | 305.60 | 314.80 | 300.00 | 3,965 | |
| 311.90 | +2.10 | +0.7% | 306.80 | 319.60 | 300.00 | 2,389 | |
| 309.80 | +2.20 | +0.7% | 306.20 | 309.80 | 306.00 | 6,520 | |
| 307.60 | -2.80 | -0.9% | 305.00 | 323.90 | 299.00 | 9,856 | |
| 310.40 | -7.80 | -2.5% | 313.50 | 319.50 | 299.00 | 13,753 | |
| 318.20 | +8.20 | +2.6% | 311.00 | 318.20 | 311.00 | 375 | |
| 310.00 | -10.00 | -3.1% | 320.10 | 325.00 | 309.00 | 16,081 | |
| 320.00 | -21.00 | -6.2% | 338.20 | 338.20 | 320.00 | 40,563 | |
| 341.00 | +11.00 | +3.3% | 341.00 | 341.00 | 341.00 | 293 | |
| 330.00 | -0.80 | -0.2% | 330.80 | 340.90 | 330.00 | 3,940 | |
| 330.80 | +1.40 | +0.4% | 330.00 | 340.70 | 330.00 | 2,276 | |
| 329.40 | -11.40 | -3.3% | 340.80 | 340.80 | 325.00 | 8,363 | |
| 340.80 | -0.50 | -0.1% | 341.30 | 341.30 | 330.10 | 2,015 | |
| 341.30 | -5.30 | -1.5% | 345.50 | 345.50 | 336.00 | 2,076 | |
| 346.60 | +11.80 | +3.5% | 334.80 | 349.90 | 333.00 | 1,775 | |
| 334.80 | -6.60 | -1.9% | 339.30 | 356.00 | 332.00 | 9,886 | |
| 341.40 | -10.10 | -2.9% | 349.90 | 366.90 | 335.00 | 23,481 | |
| 351.50 | +3.50 | +1.0% | 345.30 | 360.00 | 345.00 | 10,709 | |
| 348.00 | +5.80 | +1.7% | 348.90 | 349.00 | 340.30 | 25,155 | |
| 342.20 | -5.90 | -1.7% | 349.70 | 359.40 | 342.00 | 7,326 | |
| 348.10 | +6.60 | +1.9% | 351.80 | 360.00 | 346.30 | 18,422 | |
| 341.50 | -1.50 | -0.4% | 340.80 | 360.00 | 340.40 | 4,421 | |
| 343.00 | -9.00 | -2.6% | 364.90 | 364.90 | 343.00 | 40,554 | |
| 352.00 | -22.00 | -5.9% | 370.50 | 380.00 | 348.00 | 55,071 | |
| 374.00 | -2.40 | -0.6% | 355.00 | 380.00 | 348.00 | 51,563 | |
| 376.40 | +12.80 | +3.5% | 364.80 | 383.80 | 364.80 | 27,035 | |
| 363.60 | -40.20 | -10.0% | 390.00 | 390.00 | 362.00 | 98,699 | |
| 403.80 | -86.60 | -17.7% | 495.10 | 699.00 | 399.80 | 228,292 | |
| 490.40 | -24.50 | -4.8% | 507.00 | 517.90 | 490.00 | 10,044 | |
| 514.90 | +8.80 | +1.7% | 507.70 | 529.00 | 498.00 | 5,926 | |
| 506.10 | -9.50 | -1.8% | 515.60 | 529.00 | 506.00 | 5,303 | |
| 515.60 | -1.60 | -0.3% | 506.00 | 535.00 | 505.50 | 8,039 | |
| 517.20 | +8.20 | +1.6% | 515.20 | 538.90 | 506.00 | 1,899 | |
| 509.00 | -2.00 | -0.4% | 511.00 | 547.90 | 509.00 | 3,572 | |
| 511.00 | -26.20 | -4.9% | 537.20 | 548.90 | 511.00 | 13,744 | |
| 537.20 | +6.50 | +1.2% | 537.20 | 544.50 | 537.20 | 183 | |
| 530.70 | -2.20 | -0.4% | 532.90 | 544.90 | 510.10 | 1,157 | |
| 532.90 | +22.90 | +4.5% | 531.10 | 540.40 | 520.00 | 4,131 | |
| 510.00 | -16.00 | -3.0% | 516.00 | 539.90 | 510.00 | 10,256 | |
| 526.00 | -1.50 | -0.3% | 527.30 | 549.00 | 505.00 | 31,803 | |
| 527.50 | +26.00 | +5.2% | 504.60 | 527.50 | 504.60 | 596 | |
| 501.50 | -14.00 | -2.7% | 515.50 | 525.90 | 497.00 | 12,286 | |
| 515.50 | +14.40 | +2.9% | 508.00 | 541.80 | 508.00 | 34,817 | |
| 501.10 | -7.10 | -1.4% | 508.20 | 523.70 | 496.00 | 9,526 | |
| 508.20 | -21.50 | -4.1% | 528.40 | 528.40 | 506.00 | 2,840 | |
| 529.70 | +16.10 | +3.1% | 522.00 | 533.00 | 522.00 | 3,412 | |
| 513.60 | +16.20 | +3.3% | 514.80 | 548.70 | 505.30 | 34,137 | |
| 497.40 | -18.30 | -3.5% | 514.90 | 514.90 | 490.00 | 5,126 | |
| 515.70 | -3.10 | -0.6% | 518.80 | 521.60 | 490.00 | 18,424 | |
| 518.80 | +2.80 | +0.5% | 499.00 | 539.00 | 495.10 | 25,367 | |
| 516.00 | +22.40 | +4.5% | 508.00 | 519.00 | 508.00 | 9,819 | |
| 493.60 | -6.40 | -1.3% | 491.40 | 509.80 | 489.00 | 2,868 | |
| 500.00 | +9.00 | +1.8% | 494.50 | 500.00 | 490.00 | 5,046 |
- Ticker
- TASE:CANF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TASE
- Currency
- ILA
What changed lately
Calls
Replays
Can-Fite Biopharma (TASE:CANF) Q3 2020 Earnings Call
Mon, Nov 30, 2020 · 9:15 AM ET
Watch Transcript
Latest news
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Sep 8, 2026
Closed 352.00 (-5.9%) on Sep 8, 2026
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 18, 2026
Closed 500.40 (-3.6%) on May 18, 2026
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
May 13, 2026
Closed 514.80 (+5.1%) on May 13, 2026
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Apr 30, 2026
Closed 507.00 (+10.2%) on Apr 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Mar 30, 2026
Closed 511.80 (-2.2%) on Mar 30, 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 26, 2026
Closed 511.10 (-0.7%) on Mar 26, 2026
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 17, 2026
Closed 570.90 (-1.9%) on Mar 17, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 4, 2026
Closed 762.00 (-49.2%) on Mar 5, 2026
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Feb 17, 2026
Closed 712.00 (+4.7%) on Feb 17, 2026
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Feb 9, 2026
Closed 674.80 (+2.1%) on Feb 9, 2026
Decks
Investor Presentation (November 2025)
Investor deck · 29 slides · November 2025
Investor Presentation (February 2025)
Investor deck · 23 slides · Feb 5, 2025
Investor Presentation (September 2023)
Investor deck · 22 slides · Sep 7, 2023
Investor Presentation (March 2020)
Investor deck · 20 slides · Mar 9, 2020
Can-Fite BioPharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 36 in all · newest Sep 8, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 30, 2020
- Decks
- 13 decks · latest November 2025
Where Can-Fite BioPharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:CANF · Home listing · This page | TASE | Israel | ILA |
| NYSE American:CANF | NYSE American | United States | USD |
| BOATS:CANF | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Can-Fite BioPharma Ltd.